Maximal androgen blockade little influences bone mineral density in prostate cancer patients.
- Author:
Guo-Feng SUN
1
;
Bing YANG
;
He ZHU
;
Ning-Chen LI
;
Yan-Qun NA
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Alkaline Phosphatase; analysis; Androgen Antagonists; administration & dosage; adverse effects; therapeutic use; Bone Density; drug effects; Bone Diseases, Metabolic; etiology; Calcium; blood; urine; Humans; Male; Middle Aged; Osteoporosis; etiology; Parathyroid Hormone; analysis; Phosphorus; urine; Prostatic Neoplasms; drug therapy; metabolism; Testosterone; blood
- From: National Journal of Andrology 2012;18(11):978-981
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo determine the influence of maximal androgen blockade (MAB) on bone mineral density (BMD) in men with prostate cancer.
METHODSWe enrolled 40 men with prostate cancer treated by MAB for 7 to 12 months. We obtained the laboratory results of PSA, testosterone, serum calcium and phosphorus, 24-h urine calcium and phosphorus, alkaline phosphatase, and parathyroid hormone, measured the BMD of the lumbar spine and femoral neck by dual energy X-ray absorptiometry, recorded pain scores, and compared the results before and after the treatment.
RESULTSBefore MAB treatment, 5 (12.5%) of the patients met the BMD criteria of lumbar spine (L2-4) osteopenia, 8 (20%) lumbar spine (L2-4) osteoporosis, 13 (32.5%) left femoral neck osteopenia, and 15 (37.5%) left femoral neck osteoporosis. The PSA and testosterone levels were decreased from (52.9 +/- 69.9) microg/L and (18.9 +/- 6.5) nmol/L before MAB to (1.5 +/- 1.6) microg/L and (1.9 +/- 1.3) nmol/L after it (P<0.05). There were no statistically significant differences before and after MAB in the levels of serum calcium and phosphorus, 24-h urine calcium and phosphorus, alkaline phosphatase, and parathyroid hormone (P>0.05), nor in the BMD levels of the lumbar spine ([1.1 +/- 0.1] vs [1.1 +/- 0.2] g/cm2) and femoral neck ([0.8 +/- 0.2] vs [0.8 +/- 0.1] g/cm2), nor in the pain score ([0.6 +/- 0.2] vs [0.7 +/- 0.1], P>0.05).
CONCLUSIONMAB treatment (range from 7 to 12 months) has no significant influence on BMD in men with prostate cancer, but BMD should be measured before MAB.
